Introduction
============

Despite our increasing understanding of the mechanism of contraction and relaxation of the myometrial smooth muscle cell, our ability to prevent, or effectively treat, preterm labour has not improved in the same way. Knowledge of uterine activity is essential if we are to discover new tocolytic treatments.

Small-conductance calcium-activated potassium (SK) channels have been shown to be present in human myometrium from pregnant and non-pregnant women [@b1]--[@b4]. SK channel isoform 3 (SK3) is of particular interest as it has been shown to alter myometrial contractility and its expression is regulated throughout pregnancy [@b5]--[@b8]. We have recently studied the functionality of SK channels in myometrium from pregnant and non-pregnant women and have demonstrated that SK channel activation contribute to relaxation of the human myometrium *in vitro* [@b9]. However, the precise cellular localization of SK channels is still not obvious.

The myometrium is composed of smooth muscle cells (SMC) and interstitial cells. Of recent interest are the telocytes, formerly called interstitial Cajal-like cells (ICLC). Recently, Popescu *et al*. [@b10] have thoroughly described the ultrastructure and immunophenotype of the telocytes. Telocytes are distinct interstitial cells with characteristic long moniliform prolongations (telopodes) and CD34 positive (CD34^+^) immunoreactivity. Lately, the presence of telocytes has been identified in human and mammalian tissues and organs including heart [@b11]--[@b14], placenta [@b15], urinary tract [@b16], lungs [@b17],[@b18], pleura [@b19], blood vessels [@b20], skin [@b21], pancreas [@b22], parotid glands [@b23], intestine [@b24] and endometrium [@b25].

In this study, we examined the presence of telocytes and the molecular expression and cellular immunolocalization of SK3 channels in pregnant and non-pregnant human myometrium. SK3 channels modulators regulate human myometrial contractility by modifying telocytes function through a mechanism with which we are not yet familiar.

Materials and methods
=====================

Tissue collection
-----------------

All patients were recruited from the Department of Gynaecology and Obstetrics, Holbaek Hospital and the experiments were either performed at the Smooth Muscle Research Center, Koege Hospital or at the Department of Pathology, Naestved Hospital.

Myometrium was obtained, with informed written consent, from women undergoing elective caesarean section at term not in labour (gestational age between 37 and 40 weeks; mean maternal age 32.5; range 28--40 years; *n* = 11), or hysterectomy (mean age 46; range 35--54 years; *n* = 11). Tables[1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} describe the demographic and clinical data of pregnant and non-pregnant participants respectively. None of the women included in this study had evidence of underlying disease (hypertension, diabetes, preeclampsia, intrauterine growth restriction, etc.), and all the conceptions in the pregnant group occurred spontaneously. Biopsies were obtained from the midline of the upper lip of the uterine incision (myometrium) at elective caesarean section, or from the same part of the uterus from a macroscopic normal area at hysterectomy. The tissue specimens were immediately placed in formalin for immunohistochemical experiments and transferred at room temperature to the Department of Clinical Pathology, Naestved Hospital. Biopsies for qRT-PCR experiments were placed in RNAlater (Qiagen, Copenhagen, Denmark) immediately after dissection, and transferred to the Smooth Muscle Research Center. Upon arrival, biopsies in RNAlater were stored at 4°C overnight, and frozen at −20°C until further processing (\<2 months). The study has been approved by the local ethics committee (SJ-120).

###### 

Demographic and clinical data of non-pregnant patients

  Patient             Age, year   Clinical indication   BMI    Uterus weight, g
  ------------------- ----------- --------------------- ------ ------------------
  NP01                47          Metrorrhagia          19.6   130
  Menorrhagia                                                  
  NP02                35          Cervix dysplasia      21.2   115
  Adenomyosis uteri                                            
  NP03                43          Metrorrhagia          33     1100
  Leiomyoma                                                    
  NP04                41          Metrorrhagia          31.2   120
  NP05                53          Leiomyoma             27     570
  Ovarian cyst                                                 
  NP06                48          Prolapse              28     175
  NP07                54          Metrorrhagia          23     470
  Menorrhagia                                                  
  Adenomyosis                                                  
  NP08                42          Metrorrhagia          32.2   312
  Menorrhagia                                                  
  NP09                48          Menorrhagia           32.8   210
  Polymenorrhea                                                
  Metrorrhagia                                                 
  NP10                48          Dysmenorrhea          29.7   220
  Menorrhagia                                                  
  Polymenorrhea                                                
  NP11                47          Dysmenorrhea          21.7   240
  Hypermenorrhea                                               
  Leiomyoma                                                    

###### 

Demographic and clinical data of pregnant women

  ------------------------------------ ---------------------------------------------------------------------
  Maternal age, year                   32.5 ± 3.23
  Body mass index, kg/m^2^             26.5 ± 6.4
  Gestational age at delivery, weeks   37--40
  Indication for caesarean section     Maternal request, previous caesarean section or breech presentation
  Birthweight, kg                      3.55 ± 0.3
  Data are presented as mean ± S.D.    
  ------------------------------------ ---------------------------------------------------------------------

Immunohistochemistry
--------------------

Immunohistochemical studies were performed on paraffin sections using anti-human K~Ca~2.3 (SK3) (Cat. no. APC-025; Alomone Labs, Jerusalem, Israel); anti-human CD117 clone YR145 (Cat. no. 1522-1; Epitomics, Burlingame, CA, USA); anti-human CD34 clone QBEnd 10 (Cat. no. M7165; Dako, Glostrup, Denmark); anti-human smooth muscles actin clone 1A4 (SMA, cat. no. M0851; Dako); and anti-human CD31 clone JC/70A (Cat. no. M0823; Dako).

Briefly, dewaxing and antigen retrieval was performed using immersing slides in EnVision™ FLEX Target Retrieval Solution, High pH (Cat.no. K8004; Dako) and heated in the PT-module according to the manufacturer\'s instructions. After pre-treatment, the slides were incubated with the following primary antibodies for 30 min.: K~Ca~2.3 (SK3) (1:700); CD117 clone YR145 (1:100); smooth muscle actin clone 1A4 (1:500); CD31 clone JC/70A (1:75); and CD34 clone QBEnd 10 (1:100). The reactions were detected using the EnVision™ FLEX/HRP Detection Reagent (Cat. no K8000; Dako) standard polymer technique. In addition, signal intensity was amplified using either EnVision™ FLEX+ Mouse (LINKER) (Cat. no. K8021; Dako) or EnVision™ FLEX+ Rabbit (LINKER) (Cat. no. K8009; Dako). Finally, sections were counterstained with haematoxylin and mounted with pertex.

Double immuno-labelling experiments
-----------------------------------

Studies were performed on paraffin sections using anti-human K~Ca~2.3 (SK3) (1:350) in combination with either CD34 clone QBEnd 10 (1:50); smooth muscle actin clone 1A4 (1:100); or CD31 clone JC/70A (1:15). Following pre-treatment (described above), the slides were incubated with a mix of the primary antibodies for 60 min. The resulting reactions were detected as described elsewhere [@b26].

### Controls

Human appendix was included as positive tissue control. Negative controls were performed by omitting primary antibodies, or primary antibody mix, in double immuno-labelling experiments. In addition, the specificity of the K~Ca~2.3 (SK3) antibody was assessed using a specific blocking peptid (Alomone labs) in accordance with the manufacturer\'s instructions.

RNA extraction and cDNA synthesis
---------------------------------

Tissue biopsies were ground in liquid nitrogen in a mortar, and homogenized in 1.5 ml TriZol (Invitrogen, Naerum, Denmark) using a rotor-stator homogenizer. Total RNA was extracted from (85--150 mg) ground tissue using the Trizol method (manufacturer\'s instruction), including bromochloropropane (VWR, Herlev, Denmark) for phase-separation. The quantity of extracted RNA was checked spectrophotometrically with a nanophotometer (Implen; VWR). To ensure RNA integrity, only samples with an A260/A280 optical density (OD) ratio of 1.7--2.0 were used. A quantity of 1 μg was loaded on a 1% agarose gel containing ethidium bromide for electrophoresis and visualized using a UV-transilluminator (Uvitec; Kem-en-tec, Taastrup, Denmark). RNA (10 μg) samples were purified by DNase treatment to remove contaminating genomic DNA. This was done using an RNAse-free DNase kit according to the manufacturer\'s instructions for rigorous DNA removal (50 μl reaction) (Ambion; Applied Biosystems, Foster City, CA, USA). The quantity and purity of DNase-treated RNA was checked spectrophotometrically and with the help of gel electrophoresis.

RNA was reversely transcribed into complementary DNA (cDNA) with 4.5 μl oligo(dT) primers (100 ng/μl), and reverse transcriptase (1 μl), in a 30 μl reaction volume from 600 ng DNase treated RNA. This was done using the Affinity Script qPCR cDNA synthesis kit (Stratagene, AH Diagnostics, Aarhus, Denmark) as per the manufacturer\'s instructions. Cycling parameters were 5 min. at 25°C; 15 min. at 42°C; 5 min. at 95°C; and 30 min. at 25°C using a Mx3000P QPCR system (Stratagene, AH Diagnostics). cDNA was stored at −20°C until further processing.

Primers
-------

While primers for the gene of interest, KCNN3, and for the reference genes, GAPDH and ACTB, were designed using Primer3 (ncbi), primer properties were determined using Oligo Analyser (IDT) software. The primers were ordered from TAG-Copenhagen (Copenhagen, Denmark). The primers were designed to match all known splice variants of the given gene. To ensure primer specificity a BLAST search against the NCBI database was performed, and a melting curve analysis ensured that only one product was amplified. Primers for the additional reference genes B2M, YWHAZ, SF3A1, 18S, SDHA and TOP1 were included in a geNorm REF gene kit (PrimerDesign Ltd, Southampton, UK), which included the qbasePLUS software license.

Quantitative real-time polymerase chain reaction
------------------------------------------------

qRT-PCR was performed using the Brilliant SYBR Green QPCR Master Mix and Mx3000P QPCR system (both from AH Diagnostics). Reactions were carried out in 25 μl reaction volumes containing 20 ng of cDNA; 12.5 μl brilliant SYBR green mastermix; 0.5 μl (10 pmol/μl) of each primer; and 9.5 μl RNase-free H~2~O. Amplification was detected using SYBR green fluorescent dye with the following amplification conditions: (i) one 10 min. pre-amplification cycle at 95°C; (ii) 40 amplification cycles including 30 sec. (denaturation) at 95°C; 60 sec. (annealing) at 60°C; and 60 sec. (extension) at 72°C; (iii) 60 sec. end-amplification cycle at 95°C, followed by increasing temperature from 55 to 95°C with continuous reading of fluorescence data (dissociation curve). Standard curves were performed for the stably expressed reference genes, and for the gene of interest (KCNN3), by twofold serial dilution of a cDNA pool of all samples (0.78--100 ng).

No template, and no reverse transcription, controls were performed for each sample and primer pair when appropriate to control for contamination or primer-dimers. A ΔCq \> 10 between sample and noRT control ensured that the samples were not contaminated by any form of genomic DNA. All reactions were carried out in triplicate, both in the case of samples and that of standard curves. Cq values were calculated from the exponential phase of amplification when crossing threshold using MxPRO 4.1 software (AH Diagnostics). Cq values were transformed into relative quantities using the gene-specific PCR amplification efficiency by geNormPlus software (qbasePLUS, Biogazelle, PrimerDesign Ltd). A geometric mean of the two stable reference genes was employed as the normalization factor of the reference genes to calculate the relative expression level of KCNN3 within the two patient groups. While amplicons were sequenced to ensure KCNN3 primer specificity (Beckman Coulter Genomics, Essex, UK), a BLAST search against the NCBI database confirmed that only the gene of interest was amplified. All graphical presentations and statistics were prepared using GraphPad Prism 5.04 (GraphPad Software, San Diego, California, USA). Whereas values were presented as mean (95% CI) group differences were analysed using the Mann--Whitney test.

Results
=======

Immunohistochemistry
--------------------

To investigate the localization of SK3 channels we stained formalin-fixed paraffin-embedded pregnant and non-pregnant human myometrium. SK3 showed a strong positive staining of vascular endothelium (mainly large veins) and interstitial cells corresponding to telocytes in non-pregnant tissue (Fig.[1](#fig01){ref-type="fig"}A). In contrast, only vascular endothelium showed positive staining for SK3 in pregnant myometrium (Fig.[2](#fig02){ref-type="fig"}A). No, or only very weak, SK3 staining was found associated with SMC. CD117, an accepted marker for ICC in the digestive tract, did not label ICC in the myometrium of either pregnant or non-pregnant patients. CD117 immunoreactivity was only detected in small round cells that resemble mast cells (Figs[1](#fig01){ref-type="fig"}C and [2](#fig02){ref-type="fig"}C). In both groups, interstitial cells (resembling telocytes) intermingling smooth muscle bundles, proved to be CD34^+^ (Figs[1](#fig01){ref-type="fig"}B and [2](#fig02){ref-type="fig"}B). Vascular endothelium was also intensely stained with CD34.

![Representative immunostaining of formalin-fixed paraffin-embedded human non-pregnant myometrial section (4 μm). Strong positive staining for SK3 (A) and CD34 (B) corresponding to telocytes intermingling muscle bundles (black arrows). SK3 and CD34 were also detected in vascular endothelium (red arrows). Only normal mast cells stained for CD117 (C; magnification × 600) and section overview labelling for smooth muscles actin (D) Magnification × 200 inserts × 600.](jcmm0016-3001-f1){#fig01}

![Representative sections of human pregnant myometrial preparation. Weak staining for SK3 (A), but strong positive staining for CD34 (B) corresponding to telocytes intermingling muscle bundles (black arrows). Pregnant myometrium showed loss of SK3 in telocytes. SK3 and CD34 were also detected in vascular endothelium (red arrows). Only normal mast cells stained for CD117 (C; magnification × 600). Section overview labelling for smooth muscles actin (D) Magnification × 200 inset ×600.](jcmm0016-3001-f2){#fig02}

The double immunofluorescence labelling experiments, carried out using SK3 and CD34 antibodies, showed that telocytes displayed co-expression for SK3 and CD34 in human non-pregnant myometrium (Fig.[3](#fig03){ref-type="fig"}B); pregnant myometrium showed a lack of SK3 staining in telocytes; and vascular endothelium displayed co-expression for both SK3 and CD34 (Fig.[3](#fig03){ref-type="fig"}D). The appendiceal muscularis propria (positive tissue control) displayed the same reaction pattern: SK3^+^; CD34^+^; CD117^−^; and SMA- (single immunohistochemical investigations) and co- expression between SK3 and CD34 (double immunofluorescence labelling investigations) in telocytes intermingling smooth muscle bundles (Fig.[3](#fig03){ref-type="fig"}F).

![Double immune-fluorescence labelling for SK3 (red) and smooth muscles actin or CD34 (green) in human non-pregnant (A and B) and pregnant (C and D) myometrium and appendiceal muscularis propria (E and F). interstitial Cajal-like cells (ICLC) displayed co-expression for SK3 and CD34 (yellow reaction product) in human non-pregnant myometrium (B) and appendiceal muscularis propria (F) (arrows), whereas pregnant myometrium lacked SK3 in ICLC and only vascular endothelium displayed co-expression for both SK3 and CD34 (arrow-head). DAPI nuclear labelling in blue. Also, note the lower cellular density in pregnant myometrium. Magnification × 600.](jcmm0016-3001-f3){#fig03}

Reference gene stability
------------------------

To determine the relative expression of SK3 mRNA in pregnant and non-pregnant women, respectively, the stability of eight reference genes was evaluated. An *M* value was calculated for each candidate reference gene using the geNorm algorithm to describe the stability of the given gene in the myometrium of pregnant and non-pregnant women, independently (Fig.[4](#fig04){ref-type="fig"}). The candidate reference genes were ranked from most stable to least stable as follows: TOP1 \> SDHA \> YWHAZ \> B2M \> GAPDH \> ACTB \> 18S \> SF3A1. Of the listed genes, TOP1, SDHA and YWHAZ were found to be stably expressed and therefore considered appropriate reference genes when comparing pregnant and non-pregnant myometrium. When the stability of reference genes in pregnant and non-pregnant myometrium was evaluated separately, the genes were ranked as follows: GAPDH \> YWHAZ \> ACTB \> SDHA \> TOP1 \> SF3A1 \> B2M \> 18S, and SDHA \> TOP1 \> SF3A1 \> YWHAZ \> B2M \> ACTB \> GAPDH \> 18S respectively (data not shown). In pregnant myometrium, all of the evaluated genes proved suitable as reference genes, whereas 18S was not a suitable reference gene in the case of non-pregnant myometrium. The qbasePlus software also determined the optimal number of reference genes required to calculate a normalization factor when comparing the two groups. In the case of the present experiment, in which tissue specimens from both pregnant and non-pregnant women were employed, this was achieved by the inclusion of two reference genes, namely TOP1 and SDHA.

![Ranking of eight candidate reference genes using geNorm. geNorm ranks the candidate reference genes based on the stability parameter *M*. The lower the *M* value, the higher the expression stability. The stability is calculated from both pregnant and non-pregnant myometrium (*n* = 22). A reference gene is considered stably expressed when *M* \< 0.5.](jcmm0016-3001-f4){#fig04}

Determination of SK3 mRNA expression levels in human myometrium
---------------------------------------------------------------

The relative amount of SK3 transcript in myometrium from pregnant and non-pregnant women was determined by normalizing to the geometric mean of SDHA and TOP1. The reference target stability measure *M* was 0.238 ± 0.08. The normalized amount of SK3 transcript present in pregnant and non-pregnant myometrium was found to be 0.53 (0.39--0.73) and 1.0 (0.67--1.50) respectively \[mean (95% CI), *n* = 11\]. Thus, the SK3 mRNA was down-regulated twofold in myometrium from pregnant compared to that from non-pregnant women (*P* = 0.016) (Fig.[5](#fig05){ref-type="fig"}A). Figure[5](#fig05){ref-type="fig"}B displays the relative amount of SK3 mRNA measured in each patient, showing a pronounced variation in the SK3 transcript levels within the non-pregnant group. In contrast, a more uniform pattern was observed within the group of pregnant women.

![KCNN3 expression measured by qRT-PCR. The relative expression of KCNN3 is normalized to the geometric mean of the most stable reference genes, SDHA and TOP1. Bar chart showing expression of KCNN3 in non-pregnant (blue, *n* = 11) and pregnant (red, *n* = 11) (A) Bar chart showing KCNN3 expression in each patient (B) Values are presented as mean ± S.E.M. \**P* \> 0.05.](jcmm0016-3001-f5){#fig05}

Discussion
==========

This study combines morphological and molecular biological data to localize and quantify SK3 channel expression in human myometrium from pregnant and non-pregnant women. To our knowledge, this is the first study to provide evidence that SK3 exclusively labels a distinct population of cells in the human myometrium, known as telocytes. This work suggests that SK3 activators reduce contractility in human myometrium by modulating ICLC function.

Our immunohistochemical data revealed that in non-pregnant myometrium SK3 immunoreactivity was observed in telocytes. The telocytes stained positive for CD34, but were negative to CD117 (ICC) and SMA (smooth muscle cells). Although CD34^+^ cells were also present in pregnant myometrium, they lacked SK3 immunoreactivity. Furthermore, the immunohistochemical results showed that SK3 expression in vascular endothelium was similar between the two groups.

Previous immunohistochemical studies have identified SK3 in myometrium without fully resolving the cellular localization [@b6]. To our knowledge, we are the first group that has examined the precise cellular localization of SK3 channels in myometrium from pregnant and non-pregnant women using double immuno-labelling experiments. Furthermore, and in agreement with our observations SK3 channel protein has also been observed in CD34^+^ cells in the human gut [@b27], and Fujita *et al*. have shown that SK3 channels in the mouse intestine are colocalized with a fibroblast-like cell different from ICC [@b28].

However, previous studies showed apamin-modulated myocyte currents, which imply that SK channels are present in the myometrial SMC of pregnant rats and women [@b29],[@b30]. We cannot ignore the possibility that SK3 channels could be present in the SMC of human myometrium. One possible reason why we cannot detect SK channels in SMC using immunohistochemistry could be that the SK3 antibody used in our experiments is raised against the N-terminal of the SK3 channel. We are aware about the existence of different SK3 splice variants that differ in the N-terminals and it is feasible that the SK3 splice variant expressed in the myometrial SMC is different from that expressed in the ICLC. Furthermore, Tong *et al*. carefully reviewed much of the current knowledge regarding potassium channels in myometrium and outlines that there are some limitations when information is extrapolated from molecular data [@b31]. qRT-PCR analysis demonstrated that SK3 channel mRNA is present in human myometrium, and that the expression is higher in non-pregnant compared to pregnant tissue. The gene expression of SK3 channels in human myometrial tissue has previously been investigated. Mazzone *et al*. [@b1],[@b2] and Pierce & England [@b4] concluded that SK3 channels are down-regulated throughout pregnancy when comparing the relative level of SK3 transcript in pregnant and non-pregnant myometrium. However, they normalized SK3 transcript to 18S RNA (small subunit ribosomal RNA) and GAPDH respectively. According to our study, these reference genes are stably expressed within each group, but are not stably expressed between the two groups and are thus not optimal for normalization.

The reason why SK3 channel transcript level is lower in the uterus during pregnancy compared to that during non-pregnancy has been proposed to be the down-regulation of the SK3 channels. However, it is possible that hypertrophy and larger cell volume in the pregnant myometrium could account for these changes. Therefore, we are not sure whether the reduced amount of SK3 channel transcript is solely because of down-regulation during pregnancy, or whether it is lower in myometrium from pregnant women as a result of the decreased cell density of SMC and ICLC expressing SK3 channel.

Moreover, in the present study we found that SK3 expression varies within the non-pregnant group. This is in keeping with our immunohistochemical experiments, *i.e*. the myometrial preparations that showed a strong labelling of SK3, had a high expression of SK3 mRNA. Thus, the SK3 channel protein expression is in accordance with the mRNA expression. Interestingly, and in accordance with our study, Mazzone *et al*. also observed heterogeneity in SK3 mRNA expression within a group of human non-pregnant myometrium [@b2]. One of the reasons for this variability could be the status of the hormonal cycle when the patients were operated and the tissue collected. There is consistent data about hormones influencing the expression of several ion channels including SK channels [@b3],[@b32],[@b33]. More precisely, Pierce & England concluded that one of the mechanisms regulating SK3 channel expression occurs *via* transcriptional regulation through oestrogen modulation [@b4]. However, SK3 transcript variation is not easily linked with hormonal status in our non-pregnant patients as many of their underlying disorders were associated with hormone imbalance. Also the age of the patients could be another reason for the SK3 mRNA expression variability.

Our qRT-PCR data has provided two main findings: first, and in agreement with others, that SK3 channel transcript is lower in pregnant compared to non-pregnant myometrium; and second, that the SK3 channel transcript varies greatly within the group of non-pregnant myometrium, a possibility that has previously been underappreciated. Our present study has shown that SK3 channels are expressed in CD34^+^ cells and are down-regulated during pregnancy. As we have recently demonstrated, SK channel activation contributes to the relaxation of human myometrium *in vitro* [@b9]. Thus, although SK channels modulate uterine contractility, this does not occur directly through myocyte interaction. We therefore speculate that CD34^+^ cells may represent a novel mechanism controlling the excitability of the human uterine musculature. As hypothesized by Cretoiu *et al*. and Allix *et al*. a possible mechanism could be *via* a tyrosine-kinase independent signalling pathway [@b34],[@b35]. However, further studies are needed to address the functional aspects of CD34^+^ cells and their coupling with SMC. Such studies will lead to a better understanding of the role played by telocytes in the myometrium.
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**Figure S1** Representative immunostaining of formalin-fixed paraffin-embedded human non-pregnant (**A**) and pregnant (**B**) myometrium and appendiceal muscularis propia (**C**) showing CD117 staining. Only normal mast cell stained for CD117 in human myometrium. In contrast, ICC show CD117+ staining in appendiceal muscularis propia (C). Magnification × 600.
